DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma
NCT ID: NCT01419509
Last Updated: 2016-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
170 participants
OBSERVATIONAL
2011-08-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies DNA tests in detecting disseminated disease in tumor, blood, and bone marrow samples from patients with rhabdomyosarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma
NCT01585376
Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma
NCT01062438
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
NCT00919269
Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
NCT01433237
Biomarkers in Patients With Rhabdomyosarcoma
NCT01466283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To establish a panel of hypermethylation assays for minimal disseminated disease analysis in rhabdomyosarcoma (RMS).
* To apply the hypermethylation assays to a series of bone marrow specimens from RMS patients.
OUTLINE: Archived tumor, bone marrow, and peripheral blood samples are analyzed for DNA hypermethylation by PCR-based assays and microarray assays. Results are then compared with each patient's clinical and pathological characteristics, and outcomes. Patterns of locus hypermethylation in tumor and paired bone marrow samples are also compared.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA methylation analysis
microarray analysis
polymerase chain reaction
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with rhabdomyosarcoma (RMS)
* Tumor, bone marrow, and peripheral blood samples from the Children's Oncology Group D9803 trial of intermediate-risk RMS
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen R. Master, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ARST11B1
Identifier Type: OTHER
Identifier Source: secondary_id
ARST11B1
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02985
Identifier Type: REGISTRY
Identifier Source: secondary_id
ARST11B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.